
Opinion|Videos|August 5, 2024
Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors
Drs. Hanna and Rugo discuss possible access improvements in regards to CDK4/6 inhibitors.
Advertisement
Video content above is prompted by the following question(s):
- What is the potential role of value-based pricing models or alternative payment arrangements in improving access to CDK4/6 inhibitors for eligible patients?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration
2
FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development
3
Boosting RSV Vaccination in Older Adults Could Save Thousands
4
Cancer Care in Transition: Navigating Breakthrough Therapies Amid Economic Strain
5














































